Skip to main navigation
Skip to search
Skip to main content
UTMB Health Research Expert Profiles Home
Help & FAQ
Home
Experts
Departments
Equipment
Projects/Grants
Publications
Activities
Press/Media
Honors
Search by expertise, name or affiliation
Candidate vaccines for human Rift Valley fever
Tetsuro Ikegami
Pathology
Research output
:
Contribution to journal
›
Review article
›
peer-review
19
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Candidate vaccines for human Rift Valley fever'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Vaccine Antigen
100%
Rift Valley Fever
100%
Rift Valley Fever Vaccine
57%
Immunogenicity
28%
Investigational New Drug
28%
Illness
14%
Encephalitis
14%
Protective Immunity
14%
Public Health Risk
14%
Economic Loss
14%
Vaccination
14%
Live Attenuated
14%
Clinical Trials
14%
Sheep
14%
Cattle
14%
Phlebovirus
14%
MP-12
14%
Hemorrhagic Fever
14%
Rift Valley Fever Virus
14%
Sub-Saharan Africa
14%
Saudi Arabia
14%
Severe Disease
14%
Human Use
14%
Formalin
14%
At-risk
14%
Endemic Countries
14%
Thermal Stability
14%
Veterinary
14%
Expert Opinion
14%
Area Cover
14%
Egypt
14%
Abortion
14%
Yemen
14%
Madagascar
14%
Retinitis
14%
Phenuiviridae
14%
Goat Diseases
14%
Pharmacology, Toxicology and Pharmaceutical Science
Rift Valley Fever
100%
Rift Valley Fever Virus
27%
Disease
18%
Immunogenicity
18%
Clinical Trial
9%
Hemorrhagic Fever
9%
Encephalitis
9%
Formaldehyde
9%
Phlebovirus
9%
Thermostability
9%
Bovine
9%
Retinitis
9%
Immunology and Microbiology
Rift Valley Fever
100%
Rift Valley Fever Virus
27%
Immunogenicity
18%
Encephalitis
9%
Phlebovirus
9%
Bovine
9%
Hemorrhagic Fever
9%
Thermostability
9%